-
MicroRNA-210 Mediates Hypoxic Pulmonary Hypertension in the Newborn Lamb. Hypertension (IF 6.9) Pub Date : 2025-04-23 Xiang-Qun Hu,Rui Song,Chiranjib Dasgupta,Stephen Twum-Barimah,Taiming Liu,Abu Ahmed,Shawn F Hanson,Lubo Zhang,Arlin B Blood
BACKGROUND Pulmonary hypertension of the newborn is a life-threatening disorder characterized by elevated pulmonary vascular resistance due to maladaptation of the pulmonary circulation after birth. The etiology and mechanisms underlying pulmonary hypertension of the newborn remain unclear, hindering the development of effective treatment. We hypothesize that perinatal chronic hypoxia upregulates microRNA-210
-
Impact of NAFLD and Fibrosis on Adverse Cardiovascular Events in Patients With Hypertension. Hypertension (IF 6.9) Pub Date : 2025-04-23 Yanqiu Huang,Tingya Wan,Yuemei Hong,Xiaoyu Wang,Xu Jiang,Yang Yang,Hong Gao,Juan Ji,Liao Wang,Yang Yang,Xiaoguang Li,Hui Wang
BACKGROUND Nonalcoholic fatty liver disease (NAFLD) is a common comorbidity in hypertension. However, the impact of NAFLD and related fibrosis on hypertension and its control of cardiovascular disease (CVD) and mortality outcomes remains unclear. METHODS 12 907 and 120 639 participants with hypertension were from the National Health and Nutrition Examination Survey (NHANES) and UK Biobank (UKBB), respectively
-
Blood Pressure-Elevating and Antihypertensive Medication Prescription Trends. Hypertension (IF 6.9) Pub Date : 2025-04-22 Ashutosh Kumar,Nicole L Therrien,John I Ogwuegbu,Jun Soo Lee,Hilary K Wall,John M Flack,Sandra L Jackson
BACKGROUND Many medications can have blood pressure (BP)-elevating effects, which might negatively impact BP control among people with hypertension. This study examines trends in prescription fills for BP-elevating and antihypertensive medications, individually and concurrently, among US individuals. METHODS Quarterly trends of concurrent and individual fills for BP-elevating and antihypertensive medications
-
Effects of Blood Pressure Control on Arterial Stiffness Mechanisms in SPRINT: A Randomized Controlled Trial. Hypertension (IF 6.9) Pub Date : 2025-04-22 Ryan Pewowaruk,Byron C Jaeger,Timothy M Hughes,Bharathi Upadhya,Dalane W Kitzman,Mark A Supiano,Adam D Gepner
BACKGROUND The longitudinal impact of blood pressure (BP) control on the components of arterial stiffness has not been studied. METHODS The SPRINT (Systolic BP Intervention Trial) compared an intensive systolic BP goal (<120 mm Hg) to a standard goal (<140 mm Hg). Carotid-femoral pulse wave velocity (PWV) was measured in a subset of participants (n=605) at 0, 1, 2, and 3 years after randomization.
-
Treatment in the First Month After Hypertension Diagnosis Improves Blood Pressure Control. Hypertension (IF 6.9) Pub Date : 2025-04-21 Robert B Barrett,Benjamin Riesser,Benjamin Martin,Neha Sachdev,Michael K Rakotz,Susan E Sutherland,Brent M Egan
BACKGROUND Adults with hypertension have fewer cardiovascular events if controlled within the first 6 months of diagnosis, during which time they are excluded from many hypertension control metrics. We compared blood pressure (BP, mm Hg) control rates from 6 to 42 months in adults with hypertension who did or did not have antihypertensive treatment initiated (TI) with monotherapy during the first month
-
IGF-1 Provides Protective Role in Arteriosclerotic Cerebral Small Vessel Disease. Hypertension (IF 6.9) Pub Date : 2025-04-18 Xiangming Xu,Ming Yi,Chi Xiao,Jing Yang,Jiayu Guo,Wenli Zhou,Kun Zhou,Liuting Hu,Linfang Lan,Yuhua Fan
BACKGROUND Hypertension and advanced age are risk factors for arteriosclerotic cerebral small vessel disease (cSVD), a common cause of vascular dementia in elderly individuals. Circulating IGF-1 (insulin-like growth factor 1) levels decrease with age and are linked to age-related cognitive impairment. This study assessed the relationship between serum IGF-1 and arteriosclerotic cSVD severity in patients
-
Left Ventricular Hypertrophy or Not Left Ventricular Hypertrophy in Women With Prior Preeclampsia. Hypertension (IF 6.9) Pub Date : 2025-04-16 Erik Hedström
-
Early Blood Pressures Warrant Attention in Modern Clinical Data Infrastructure. Hypertension (IF 6.9) Pub Date : 2025-04-16 Steven J Korzeniewski
-
Epidemiology and Pathophysiology of Preeclampsia: New Mechanistic Insights. Hypertension (IF 6.9) Pub Date : 2025-04-16 Gaetano Santulli,Urna Kansakar,Fahimeh Varzideh
-
PRERISK Study: A Randomized Controlled Trial Evaluating a sFlt-1/PlGF-Based Calculator for Preeclampsia Hospitalization. Hypertension (IF 6.9) Pub Date : 2025-04-16 Anna C M Kluivers,Rugina I Neuman,Langeza Saleh,Henk Russcher,Ingrid A Brussé,Jerome M J Cornette,Eric A P Steegers,Marijke C van der Weide,Joris van Drongelen,Ralph R Scholten,Antonius E van Herwaarden,Sanne J Gordijn,Anneke C Muller Kobold,Wessel Ganzevoort,Sharon M Wesselius,Maurits C F J de Rotte,Robert Aardenburg,Maarten Raijmakers,Willy Visser,A H Jan Danser
BACKGROUND A model based on the soluble Fms-like tyrosine kinase-1/placental growth factor ratio, gestational age, and the urinary protein-to-creatinine ratio (PRERISK calculator) has been developed to predict preeclampsia-related maternal-fetal complications. Here, we tested whether this model can reduce hospital admissions without increasing complication rates among women with suspected or confirmed
-
Placental Endocannabinoid System: Focus on Preeclampsia and Cannabis Use. Hypertension (IF 6.9) Pub Date : 2025-04-16 Madhavi S Harhangi,Sinno H P Simons,Hilmar H Bijma,Anna Nguyen,Tuong-Vi Nguyen,Tu'uhevaha Kaitu'u-Lino,Irwin K M Reiss,A H Jan Danser,Michelle Broekhuizen
BACKGROUND The endocannabinoid system (ECS) plays an important role in the early stages of pregnancy, while cannabis use during pregnancy associates with a greater risk of preeclampsia. This study quantified the placental ECS component mRNA levels in gestational age-matched healthy pregnant women, women with preeclampsia, and women who used cannabis throughout their pregnancy. Next, it compared the
-
When Something Does Not Match Up: A Case of Interarm Blood Pressure Discrepancy. Hypertension (IF 6.9) Pub Date : 2025-04-16 Thomas J Hanlon,Rebecca DiBlasio,Jennifer Weintraub,Kelsey B Bryant
-
Cardiovascular Disease Risk Awareness and Prevention Perspectives Following Hypertensive Disorders of Pregnancy. Hypertension (IF 6.9) Pub Date : 2025-04-16 Nadine Sunji,Natalia Tovar,Kathryn E Flynn,Alisse Hauspurg,Anna Palatnik
-
Cuffless Blood Pressure Measurement: Where Do We Actually Stand? Hypertension (IF 6.9) Pub Date : 2025-04-15 Ramakrishna Mukkamala,Sanjeev G Shroff,Konstantinos G Kyriakoulis,Alberto P Avolio,George S Stergiou
Cuffless blood pressure (BP) measurement offers considerable potential for clinical practice but is a challenging technological field. Many are investigating pulse wave analysis with or without pulse arrival time in which machine learning is applied to pulsatile waveforms obtained with mobile devices (eg, wristbands, smartphones) to estimate BP. These methods generally require individual user calibration
-
Asian Expert Consensus on Nocturnal Hypertension Management. Hypertension (IF 6.9) Pub Date : 2025-04-11 Jing Liu,Yan Li,Kei Asayama,Xin-Jun Zhang,Hao-Min Cheng,Sungha Park,Kazuomi Kario,Erkin Mirrakhimov,Ji-Guang Wang
There is consistent and strong evidence that nighttime blood pressure is a better predictor of target organ damage and cardiovascular events, and the prevalence of nocturnal hypertension is high in all populations but higher in Asians than Europeans. Excessive salt intake and salt sensitivity have long been believed to be risk factors for elevated nighttime blood pressure in Asians. For various reasons
-
Endothelial SMAD4 Deficiency Promotes Pulmonary Hypertension by Impairing Cell Adhesion and Extracellular Matrix Organization. Hypertension (IF 6.9) Pub Date : 2025-04-11 Wenyu Lv,Xinyu Gu,Lei Zeng,Keli Liu,Yunhua Li,Xun Chen,Xuan Zhang,Xuetong Zhou,Jiaqi He,Yong Dai,Jingfeng Wang,Feng Zhang,Yangxin Chen
BACKGROUND Aberrant BMPR2 (bone morphogenetic protein receptor 2) signaling is associated with the pathogenesis of pulmonary hypertension. SMAD4 is an essential downstream effector of BMPR2 signaling, but whether and how it participates in pulmonary hypertension are unclear. METHODS Globally and vascular cell-specifically inducible knockout mouse models were used to examine the role of SMAD4 deficiency
-
Preeclamptic Placental CD19+ B Cells Are Causal to Hypertension During Pregnancy. Hypertension (IF 6.9) Pub Date : 2025-04-02 Owen Thomas Herrock,Nathan Campbell,Evangeline Deer,Lorena M Amaral,Darby Whitney,Rachael Morris,Kedra Wallace,Ty Warren Turner,E Hawthorne Cleveland,Sheila Belk,George W Booz,Denise C Cornelius,Babbette LaMarca
BACKGROUND Patients with preeclampsia exhibit hypertension and chronic inflammation characterized by CD (cluster determinant) 4+T cells, B cells secreting AT1-AA (agonistic autoantibody against the angiotensin II type 1 receptor), inflammatory cytokines, and complement activation. Importantly, a history of COVID-19 during pregnancy is associated with an increased incidence of a preeclampsia-like phenotype
-
Disparities in Postpartum Care After a Hypertensive Disorder of Pregnancy in the United States. Hypertension (IF 6.9) Pub Date : 2025-04-02 Megan M McLaughlin,Neda Ghaffari,Catherine Lee,Malamo E Countouris,Phoebe Ashley,Amanda Schnell-Herringer,Divya P Mallampati,Juan M Gonzalez,Alexis L Beatty
BACKGROUND The postpartum period is a critical time for blood pressure monitoring and cardiovascular risk factor modification in individuals with hypertensive disorders of pregnancy (HDP), who are at increased risk for cardiovascular disease. METHODS We analyzed data from the Pregnancy Risk Assessment Monitoring System, a nationally representative US population-based survey of postpartum women with
-
Total and Free Placental Growth Factor Levels During Preeclampsia and Fetal Growth Restriction. Hypertension (IF 6.9) Pub Date : 2025-04-02 Amélie Jungelson,Audrey Ridoux,Marion Barthe,Diane Redel,Houria Abbas,Bassam Haddad,S Ananth Karumanchi,Edouard Lecarpentier
BACKGROUND The objective of this study was to evaluate total circulating PlGF (placental growth factor) and free PlGF concentrations to provide insights into the mechanisms of decreased PlGF noted in preeclampsia and fetal growth restriction. METHODS We conducted a retrospective single-center study in pregnant women receiving care for suspected preeclampsia or fetal growth restriction. Serum angiogenic
-
Early Pregnancy Blood Pressure Trajectories and Hypertension Years After Pregnancy. Hypertension (IF 6.9) Pub Date : 2025-04-02 James M Roberts,Stacey E Alexeeff,Baiyang Sun,Mara Greenberg,Alexis King,Mai N Nguyen-Huynh,Alan S Go,Erica P Gunderson
BACKGROUND Hypertensive disorders of pregnancy (HDP) increase cardiovascular disease risk. Blood pressure (BP) trajectories ≤20 weeks' gestation predict HDP outcomes. We hypothesized that early-pregnancy BP patterns stratify risk of developing hypertension years after pregnancy. METHODS This prospective cohort of 174 774 women without prior hypertension, kidney, liver, or heart disease, or history
-
ACE Inhibition to Distinguish Low-Renin Hypertension From Primary Aldosteronism. Hypertension (IF 6.9) Pub Date : 2025-03-31 Cheng-Hsuan Tsai,Jenifer M Brown,Stefanie Parisien-La Salle,Andrew Newman,Vin-Cent Wu,Yen-Hung Lin,Anand Vaidya
BACKGROUND Primary aldosteronism (PA) is a distinct cause of low-renin hypertension (LRH), characterized by inappropriate aldosterone production. We investigated the distinction between LRH and PA by leveraging the physiological effects of angiotensin-converting enzyme inhibition. METHODS We conducted a retrospective cohort study including 756 patients with LRH who underwent a captopril challenge test
-
Priorities for Research on Hypertension Care Delivery: A WHO Report Executive Summary. Hypertension (IF 6.9) Pub Date : 2025-03-20 Kunihiro Matsushita,Sonia Y Angell,Lawrence J Appel,Helen Bygrave,Jennifer Cohn,Robert Kalyesubula,Prabhdeep Kaur,Andrew E Moran,Margaret Mswema,Veronica Schoj,Aletta E Schutte,Ruitai Shao,Xin-Hua Zhang,Pedro Ordunez,Taskeen Khan
BACKGROUND In 2024, the World Health Organization released a report on Priorities for Research on Hypertension Care Delivery. This article provides its executive summary. METHODS The World Health Organization and its technical experts formed a leadership team, developed a scope and objectives, created a thematic framework, developed a survey for each theme, and identified research priorities. The 5
-
Identification of Novel Therapeutic Targets for Hypertension. Hypertension (IF 6.9) Pub Date : 2025-03-20 Zhiwei Zheng,Rumeng Chen,Menghua Liu,Yining Ding,Shuling Xu,Chunyan Hou,Sen Li
BACKGROUND Persistently high blood pressure remains the leading risk factor for mortality worldwide. This study aims to identify potential drug targets for hypertension. METHODS Mendelian randomization was used to identify therapeutic targets for hypertension. Genome-wide association study summary statistics were obtained from the UK Biobank and FinnGen study. Cis-expression quantitative trait loci
-
Contemporary Use of an Old Drug: Minoxidil for Resistant Hypertension. Hypertension (IF 6.9) Pub Date : 2025-03-19 Michael Bursztyn,Iddo Z Ben-Dov
-
Clonal Hematopoiesis of Indeterminate Potential and Incident Hypertension: Results From the Women's Health Initiative. Hypertension (IF 6.9) Pub Date : 2025-03-19 Bernhard Haring,Aaron K Aragaki,Daichi Shimbo,Stephen R Rapp,Charles B Eaton,Michael J LaMonte,Jean Wactawski-Wende,Matthew A Allison,Aladdin H Shadyab,Jacques E Rossouw,Eric A Whitsel,Nora Franceschini,Charles Kooperberg,Pinkal Desai,Michael S Simon,Michael Böhm,Pradeep Natarajan,Sylvia Wassertheil-Smoller,JoAnn E Manson
-
How Low Can You Go? Flagging a Role for Hypotension in Cognitive Decline With Intensive Blood Pressure Therapy. Hypertension (IF 6.9) Pub Date : 2025-03-19 Clinton B Wright,Hyun Song
-
Channeling Hope in the Expanding Landscape of Therapy for Pulmonary Hypertension: Potential Role for Piezo2. Hypertension (IF 6.9) Pub Date : 2025-03-19 Jochen Steppan,Dan E Berkowitz
-
Left Out in the Cold? The Sympathetic Signature of Cold-Induced Hypertension. Hypertension (IF 6.9) Pub Date : 2025-03-19 John W Osborn,Brianna Dailey-Krempel
-
Endothelin Antagonism: A New Era for Resistant Hypertension? Hypertension (IF 6.9) Pub Date : 2025-03-19 Gavin B Chapman,Neeraj Dhaun
-
Controversy in Hypertension: Pro-Side of the Argument Using Artificial Intelligence for Hypertension Diagnosis and Management. Hypertension (IF 6.9) Pub Date : 2025-03-17 Antonis A Armoundas,Faraz S Ahmad,Zachi I Attia,Dimitrios Doudesis,Rohan Khera,Konstantinos G Kyriakoulis,George S Stergiou,W H Wilson Tang
Hypertension presents the largest modifiable public health challenge due to its high prevalence, its intimate relationship to cardiovascular diseases, and its complex pathogenesis and pathophysiology. Low awareness of blood pressure elevation and suboptimal hypertension diagnosis serve as the major hurdles in effective hypertension management. Advances in artificial intelligence in hypertension have
-
Determinants of Cardio-Ankle Vascular Index and Heart-Thigh β Index in a US Cohort: The MESA. Hypertension (IF 6.9) Pub Date : 2025-03-07 Hamed Tavolinejad,Kevin E Boczar,Bart Spronck,Hannah Maynard,Alain G Bertoni,Sanjiv J Shah,Julio A Chirinos
BACKGROUND The cardio-ankle vascular index (CAVI) and heart-thigh β index (htβ) assess arterial stiffness by correcting pulse wave velocity for blood pressure to achieve less dependency on blood pressure variations. Normative data for these markers among US communities are lacking. We aimed to assess the determinants and normative values of CAVI and htβ. METHODS MESA (Multi-Ethnic Study of Atherosclerosis)
-
Pregnancy Metal Mixtures and Blood Pressure and Hypertension in Mid-Life: A Prospective U.S. Cohort Study. Hypertension (IF 6.9) Pub Date : 2025-03-06 Mingyu Zhang,Izzuddin M Aris,Andres Cardenas,Sheryl L Rifas-Shiman,Pi-I Debby Lin,Long H Ngo,Emily Oken,Marie-France Hivert,Stephen P Juraschek
BACKGROUND The long-term associations between metal mixtures in pregnancy and women's mid-life blood pressure (BP) and hypertension remain unclear. METHODS In Project Viva (enrolled 1999-2002), we measured nonessential (arsenic, barium, cadmium, cesium, mercury, lead) and essential metals (copper, magnesium, manganese, selenium, zinc) in red blood cells, along with folate and vitamin B12 in plasma
-
Association of Podometrics Findings in Patients With Hypertension and Type 2 Diabetes: A Retrospective Analysis. Hypertension (IF 6.9) Pub Date : 2025-03-06 Christopher Paschen,Maximilian C Koeller,Helga Schachner,Maja Nackenhorst,Johannes Kläger,Andre Oszwald,Katharina Dörr,Michael Kammer,Nicolas Kozakowski,Andrew Rees,Renate Kain,Manfred Hecking,Rainer Oberbauer,Heinz Regele
BACKGROUND Arterial hypertension (HTN) and type 2 diabetes (T2DM) are contributors to chronic kidney disease leading to glomerulomegaly and podocyte loss. Enlarged glomeruli and podocyte depletion are associated with kidney disease progression. This retrospective study aimed to investigate morphometric changes in patients with HTN and the contribution of coexisting T2DM in HTN. METHODS Glomerular and
-
ACLY Promotes Cardiac Fibrosis via the Regulation of DNL and Histone Acetylation. Hypertension (IF 6.9) Pub Date : 2025-03-06 Naoya Kuwahara,Manabu Nagao,Masakazu Shinohara,Kenta Kaneshiro,Takuo Emoto,Takeshi Yoshida,Terunobu Fukuda,Makoto Nishimori,Seimi Satomi-Kobayashi,Hiromasa Otake,Ken-Ichi Hirata,Tatsuro Ishida,Ryuji Toh
BACKGROUND ATP citrate lyase (ACLY) is a key enzyme in de novo lipogenesis that generates acetyl-CoA from citrate. Although fatty acids are required for energy production and biomass synthesis in the heart, the regulatory mechanisms of ACLY-mediated de novo lipogenesis in pathological cardiac fibroblasts remain unknown. The aim of this study was to investigate the biological role of ACLY in cardiac
-
Youth Blood Pressure and Target Organ Injury Markers: The SHIP AHOY Study. Hypertension (IF 6.9) Pub Date : 2025-02-27 Gilad Hamdani,Elaine M Urbina,Stephen R Daniels,Bonita E Falkner,Michael A Ferguson,Joseph T Flynn,Coral D Hanevold,Julie R Ingelfinger,Philip R Khoury,Marc B Lande,Kevin E Meyers,Joshua Samuels,Mark Mitsnefes
BACKGROUND Hypertension in adolescence is associated with subclinical target organ injury. We aimed to determine whether different blood pressure thresholds were associated with an increasing number of target organ injury markers in healthy adolescents. METHODS A total of 244 participants (mean age 15.5±1.8 years, 60.1% male) were studied. Participants were divided based on systolic clinic and systolic
-
Hypertension Prevention and Healthy Life Expectancy in Black Adults: The Jackson Heart Study. Hypertension (IF 6.9) Pub Date : 2025-02-26 Kathryn Foti,Yiyi Zhang,Susan E Hennessy,Lisandro D Colantonio,Lama Ghazi,Shakia T Hardy,Milla Arabadjian,Rushelle Byfield,Valy Fontil,Cora E Lewis,Daichi Shimbo,Paul Muntner,Brandon K Bellows
BACKGROUND The impact of preventing hypertension and maintaining normal blood pressure (BP) on life expectancy and healthy life expectancy (HLE) among Black adults, who are disproportionately affected by hypertension, has not been quantified. METHODS We used a discrete event simulation to estimate life expectancy and HLE among a cohort of Black adults from the Jackson Heart Study (n=4933) from age
-
Nationwide, Pragmatic, Direct-to-Patient Primary Aldosteronism Testing Program. Hypertension (IF 6.9) Pub Date : 2025-02-21 Jenifer M Brown,Laura C Tsai,Eva E Abel,Arnaldo Ferrebus,Anna E Moore,Yvonne M Niebuhr,Bassil Bacare,Brooke Honzel,Julia Milks,Kristen Foote,Andrew J Newman,Wasita W Parksook,Anand Vaidya
BACKGROUND Primary aldosteronism, an endocrinopathy present in ≥10% to 25% of patients with hypertension, confers excess cardiovascular risk that can be mitigated with aldosterone-directed therapy. However, only 2% of eligible patients undergo guideline-recommended screening. This study aimed to bypass clinical inertia and identify people with primary aldosteronism using pragmatic, direct-to-patient
-
Persistence of a Proteomic Signature After a Hypertensive Disorder of Pregnancy. Hypertension (IF 6.9) Pub Date : 2025-02-21 Mark A Hlatky,Chi-Hung Shu,David K Stevenson,Gary M Shaw,Marcia L Stefanick,Heather A Boyd,Mads Melbye,Xi Du Plummer,Oshra Sedan,Ronald J Wong,Nima Aghaeepour,Virginia D Winn
BACKGROUND A hypertensive disorder of pregnancy is associated with a higher risk of cardiovascular disease later in life, but the potential mechanistic links are unknown. METHODS We recruited 2 groups of women, 1 during pregnancy and another at least 2 years after delivery. Cases had a hypertensive disorder of pregnancy, and controls had a normotensive pregnancy. The pregnancy cohort had study visits
-
Under Pressure: Renal Artery Stenosis Treatment for Resistant Hypertension. Hypertension (IF 6.9) Pub Date : 2025-02-19 Emma L Hanlon,Brett J Carroll,Anna K Krawisz,Christian Mewaldt,Eric A Secemsky,Jennifer L Cluett
-
Mediation of Social Determinants and Hypertension by Epigenetic Age in CARDIA. Hypertension (IF 6.9) Pub Date : 2025-02-19 Mindy D Szeto,Hongyan Ning,Havisha Pedamallu,Yinan Zheng,Lisa Schneper,Brian Joyce,Kyeezu Kim,Kiarri N Kershaw,Orna Reges,Lifang Hou,Norrina B Allen,Daniel A Notterman,Donald M Lloyd-Jones
-
Epigenetic Aging: A Mechanism by Which Social Determinants Increase the Risk of Hypertension? Hypertension (IF 6.9) Pub Date : 2025-02-19 Alexander Chaitoff,Daichi Shimbo,Adam P Bress
-
Vascular Smooth Muscle Cell TG2 Promotes DOCA/Salt-Induced Arterial Stiffness and Hypertension. Hypertension (IF 6.9) Pub Date : 2025-02-19 Annayya R Aroor,Huma Naz,Jack Hulse,Taylor J Kelty,Neekun Sharma,Guanghong Jia,Adam Whaley-Connell,R Scott Rector,Camila Manrique-Acevedo,Guido Lastra
-
Closing the Gap in Global Disparities in Hypertension Control. Hypertension (IF 6.9) Pub Date : 2025-02-19 Shiva Raj Mishra,Gautam Satheesh,Vishnu Khanal,Tu N Nguyen,Dean Picone,Niamh Chapman,Richard I Lindley
-
Clonal Hematopoiesis Increases Hypertension and Sympathetic Activity and Is Reversed by Renal Denervation. Hypertension (IF 6.9) Pub Date : 2025-02-19 Ariel H Polizio,Lucila Marino,Luca Rolauer,Heather Doviak,Maria Grandoch,Stefano Toldo,Kenneth Walsh
-
Macrophages Regulate Inflammatory Vascular Remodeling in Pulmonary Hypertension. Hypertension (IF 6.9) Pub Date : 2025-02-19 Fahimeh Varzideh,Imma Forzano,Emanuele Farroni,Pasquale Mone,Urna Kansakar,Gaetano Santulli
-
Environmental Hypertensionology and the Mosaic Theory of Hypertension. Hypertension (IF 6.9) Pub Date : 2025-02-19 Sanjay Rajagopalan,Robert D Brook,Thomas Münzel
Hypertension is a multifactorial condition influenced by the intricate interplay of biological and genetic determinants. The growing field of Environmental Hypertensionology endorses the outsized role of environmental factors in the pathogenesis and exacerbation of hypertension. It provides a clinical approach to address these factors at the individual and societal levels. Environmental stressors contributing
-
GWAS for Defining the Pathogenesis of Hypertension: Have They Delivered? Hypertension (IF 6.9) Pub Date : 2025-02-12 Matthew R Alexander,Todd L Edwards,David G Harrison
Genome-wide association studies have identified >3500 associated single nucleotide polymorphisms and over 1000 independent loci associated with hypertension. These individually have small effect sizes, and few associated loci have been experimentally tested for causal roles in hypertension using animal models or in humans. Thus, methods to prioritize and maximize the relevance of identified single
-
East and South Asian-Specific Blood Pressure Trajectories and Cardiovascular Disease. Hypertension (IF 6.9) Pub Date : 2025-02-12 So Mi J Cho,Sarah Urbut,Yunfeng Ruan,Aarushi Bhatnagar,Shriienidhie Ganesh,Whitney E Hornsby,Romit Bhattacharya,Michael C Honigberg,Stephen P Juraschek,Eugene Yang,Daichi Shimbo,Pradeep Natarajan
BACKGROUND Cardiovascular disease (CVD) risk differs across Asian subgroups, possibly due to differences in hypertension burden. We characterized lifetime blood pressure (BP) trajectories for East and South Asian individuals and compared their associations with CVD risk. METHODS Among 148 872 UK Biobank participants with primary care utilization data, life course BP trajectories were fitted as a function
-
Aspirin Improves Uterine Artery Function in Hypercholesterolemic Preeclampsia. Hypertension (IF 6.9) Pub Date : 2025-02-12 Amanda A de Oliveira,Floor Spaans,Murilo E Graton,Angie Stokes,Raven Kirschenman,Anita Quon,Christy-Lynn M Cooke,Sandra T Davidge
BACKGROUND Excessive hypercholesterolemia in pregnancy increases the risk of preeclampsia (HC-PE), though the mechanisms remain unclear. We recently showed that uterine artery function is impaired in HC-PE pregnancies via activation of the TLR4 (toll-like receptor 4)/PGHS1 (prostaglandin H synthase 1) pathway. Low-dose aspirin lowers preeclampsia risk in high-risk pregnancies by inhibiting PGHS1, but
-
Role of Inflammatory Biomarkers in Mediating Causal Effect of Life Course Body Composition on Hypertension. Hypertension (IF 6.9) Pub Date : 2025-02-12 Liwan Fu,Yan Li,Hong Cheng,Jingfan Xiong,Pei Xiao,Hongbo Dong,Xinying Shan,Yanyan Li,Jie Mi
BACKGROUND The mediating role of inflammatory biomarkers in the causal relationship between body composition and hypertension remains unclear and requires further investigation. METHODS This study used a combination of retrospective observational analysis and Mendelian randomization approaches. Observational data were derived from 4717 Chinese children and adolescents aged 6 to 18 years who underwent
-
Prenatal Psychosocial Stressors and Blood Pressure Across 4 Years Postpartum. Hypertension (IF 6.9) Pub Date : 2025-02-10 Noelle Pardo,Sandrah P Eckel,Zhongzheng Niu,Rima Habre,Tingyu Yang,Xinci Chen,Mario J Vigil,Brendan H Grubbs,Laila Al-Marayati,Nathana Lurvey,Claudia M Toledo-Corral,Jill Johnston,Genevieve Dunton,Carrie V Breton,Theresa M Bastain,Shohreh F Farzan
BACKGROUND Psychosocial stress is a cardiovascular risk factor; however, little is known about whether prenatal psychosocial stressors influence postpartum cardiovascular health. We aimed to examine the associations of multiple measures of prenatal psychosocial stress on maternal blood pressure (BP) in the first 4 years after birth. METHODS Among 225 MADRES cohort (Maternal and Developmental Risks
-
Autonomous Epinephrine Release by KCNJ5 Mutation Drives Familial Thoracic Aortic Aneurysm and Dissection. Hypertension (IF 6.9) Pub Date : 2025-02-05 Yanyu Duan,Chenglong Wu,Zhenghong Lai,Qunxing Yuan,Naixing Hu,Shaoqiang Liu,Ziyou Liu
BACKGROUND The pathophysiology of familial thoracic aortic aneurysm and dissection (TAAD) is linked to genetic variants that affect aortic components. Although hypertension is a risk factor for TAAD, the precise genetic link remains unclear. METHODS A family with autosomal dominant TAAD complicated by hypertension was studied to identify candidate mutations. The effect of the identified mutation on
-
MYSM1 Mediates Cardiac Parthanatos and Hypertrophy by Deubiquitinating PARP1. Hypertension (IF 6.9) Pub Date : 2025-02-05 Xin Zhong,Jianjiang Xu,Xiaowen Shi,Yiting Lyu,Yuanyuan Qian,Zimin Fang,Zixuan Wang,Jincheng Xing,Bozhi Ye,Jiajun Xu,Jibo Han
BACKGROUND Cardiac hypertrophy constitutes the primary pathological basis for heart failure and exerts a considerable influence on morbidity and mortality. Deubiquitinating enzymes are crucial regulators of protein degradation and play a pivotal role in cardiac pathophysiology. This study aimed to clarify the involvement of a deubiquitinating enzyme, MYSM1 (Myb-like, SWIRM [Swi3p, Rsc8p and Moira]
-
Downregulated PSME3 Contributes to Severe Preeclampsia by Promoting Trophoblast Cell Apoptosis. Hypertension (IF 6.9) Pub Date : 2025-02-05 Lin Liu,Hui Chen,Renfei Wu,Qiongyao Wang,Qiujing Guan,Yang Chen,Siyuan Cao,Longying Tang,Zaijun Lin,Lei Li,Xiaoli Ge
BACKGROUND Severe preeclampsia (sPE) is a serious condition posing risks to both maternal and fetal health. Based on mass spectrometry analysis, we identified a key protein, PSME3 (proteasome activator subunit 3), an 11S proteasome activator, whose protein level was significantly downregulated in sPE placentas and whose function in sPE remains unknown. METHODS PSME3 protein levels in human placental
-
Central Interaction of 2-Methoxyestradiol and Lipoxygenase in AngII-Hypertension. Hypertension (IF 6.9) Pub Date : 2025-02-04 Shubha R Dutta,Purnima Singh,Chi Young Song,Ji Soo Shin,Kafait U Malik
BACKGROUND Our previous findings that arachidonic acid-12/15-lipoxygenase (LOX)-generated metabolite 12(S)-HETE contributes to angiotensin II (AngII)-induced hypertension and 17β-estradiol protects from AngII-induced hypertension via its cytochrome P450 (CYP)1B1-generated metabolite 2-methoxyestradiol in the paraventricular nucleus (PVN) in female mice led us to test the hypothesis that 2-methoxyestradiol
-
Associations of Lipid-Lowering Drugs With Blood Pressure and Fasting Glucose: A Mendelian Randomization Study. Hypertension (IF 6.9) Pub Date : 2025-02-04 Beiping Song,Lulu Sun,Xiaoli Qin,Jiawen Fei,Quan Yu,Xinyue Chang,Yu He,Yi Liu,Mengyao Shi,Daoxia Guo,Ouxi Shen,Zhengbao Zhu
BACKGROUND Observational studies have linked LDL-C (low-density lipoprotein-cholesterol)-lowering drugs with lower blood pressure (BP) and higher fasting glucose, but the causality remains unclear. We conducted a drug target Mendelian randomization study to assess the causal associations of genetically proxied inhibition of HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase), PCSK9 (proprotein
-
Efficacy and Safety of Aldosterone Synthase Inhibitors for Hypertension: A Meta-Analysis of Randomized Controlled Trials and Systematic Review. Hypertension (IF 6.9) Pub Date : 2025-01-31 Luigi Marzano,Matteo Merlo,Nicola Martinelli,Francesca Pizzolo,Simonetta Friso
BACKGROUND Hypertension is a major global health issue. Aldosterone synthase inhibitors (ASIs) have emerged as a promising therapeutic strategy for blood pressure control. METHODS A thorough search of the MEDLINE and Embase databases up to March 30, 2024, identified randomized trials comparing ASIs with a placebo for hypertension treatment. Data extraction was done independently by 2 authors. Both
-
The Long-Term Blood Pressure Trends Following a Remote Hypertension Intervention: A Secondary Analysis of the Digital Care Transformation - Remotely Delivered Hypertension Management Program. Hypertension (IF 6.9) Pub Date : 2025-01-31 Shahzad Hassan,Alexander J Blood,David Zelle,Sanjay Kumar,Kavishwar Wagholikar,Daniel Gabovitch,Christopher P Cannon,Naomi Fisher,Benjamin M Scirica
BACKGROUND Hypertension is a major cardiovascular risk factor, yet traditional care often results in suboptimal blood pressure (BP) control at the population level. We implemented a remote hypertension management program that monitored home BP and titrated medications per algorithm. This study assessed the program's long-term effects by examining participants' office BP up to 42 months post-enrollment
-
Ripple Effects of Early Life Stress on Vascular Health. Hypertension (IF 6.9) Pub Date : 2025-01-30 Cailin E Kellum,Gillian C Kelly,Jennifer S Pollock
The term early life stress encompasses traumatic events occurring before the age of 18 years, such as physical abuse, verbal abuse, household dysfunctions, sexual abuse, childhood neglect, child maltreatment, and adverse childhood experiences. Adverse psychological experiences in early life are linked to enduring effects on mental and physical health in adulthood. In this review, we first describe
-
Abolition of Aorticorenal Ganglia Pacing Responses Improves Denervation Efficacy. Hypertension (IF 6.9) Pub Date : 2025-01-30 Poornima Balaji,Xingzhou Liu,Vu Toan Tran,Michael A Barry,Albert Vien,Edward Yang,Duc Minh Nguyen,Urja Patel,Juntang Lu,Shirley Alvarez,Sushil Bandodkar,Winny Varikatt,Alistair McEwan,Stuart P Thomas,Pierre C Qian
BACKGROUND Transcatheter renal denervation (RDN) remains inconsistent despite developments in ablation technologies, due to the lack of an intraprocedural physiological end point. The aim of this study was to identify if aorticorenal ganglion (ARG) guided RDN using microwave (MW) catheter leads to more consistent denervation outcomes compared with empirical MW ablation. METHODS Pigs underwent sham